Compare DCOM & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCOM | ANIP |
|---|---|---|
| Founded | 1864 | 2001 |
| Country | United States | United States |
| Employees | 902 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | N/A | 1999 |
| Metric | DCOM | ANIP |
|---|---|---|
| Price | $39.24 | $82.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $37.80 | ★ $110.00 |
| AVG Volume (30 Days) | 214.3K | ★ 274.3K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $21.40 | $21.01 |
| Revenue Next Year | $12.65 | $17.59 |
| P/E Ratio | ★ $14.81 | $63.81 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $25.63 | $62.61 |
| 52 Week High | $40.53 | $99.50 |
| Indicator | DCOM | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 58.41 |
| Support Level | $34.86 | $76.73 |
| Resistance Level | N/A | $83.61 |
| Average True Range (ATR) | 0.86 | 2.27 |
| MACD | 0.21 | 0.36 |
| Stochastic Oscillator | 65.09 | 89.81 |
Dime Community Bancshares Inc operates as a holding company. The company gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, and mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.